Reduced plasma levels of glucagon-like peptide-1 in elderly men are associated with impaired glucose tolerance but not with coronary heart disease
Besides the insulinotropic effects of glucagon-like peptide-1 (GLP-1) mimetics, their effects on endothelial dysfunction and myocardial ischaemia are of interest. No previous study has investigated associations between plasma levels of GLP-1 and CHD.
We investigated longitudinal relationships of fasting GLP-1 with the dynamic GLP-1 response after OGTT (difference between 60 min OGTT-stimulated and fasting GLP-1 levels [ΔGLP-1]) and CHD in a population-based cohort of 71-year-old men. In the same cohort, we also cross-sectionally investigated the association between stimulated GLP-1 levels and: (1) cardiovascular risk factors (blood pressure, lipids, urinary albumin, waist circumference and insulin sensitivity index [M/I] assessed by euglycaemic–hyperinsulinaemic clamp); and (2) impaired glucose tolerance (IGT) and type 2 diabetes mellitus.
During the follow-up period (maximum 13.8 years), of 294 participants with normal glucose tolerance (NGT), 69 experienced a CHD event (13.8 years), as did 42 of 141 with IGT and 32 of 74 with type 2 diabetes mellitus. ΔGLP-1 did not predict CHD (HR 1.0, 95% CI 0.52–2.28). The prevalence of IGT was associated with ΔGLP-1, lowest vs highest quartile (OR 0.3, 95% CI 0.12–0.58), with no such association for type 2 diabetes mellitus (OR 1.0, 95% CI 0.38–2.86). M/I was significantly associated with ΔGLP-1 in the type 2 diabetes mellitus group (r = 0.38, p < 0.01), but not in the IGT (r = 0.11, p = 0.28) or NGT (r = 0.10, p = 0.16) groups.
Impaired GLP-1 secretion is associated with IGT, but not with type 2 diabetes mellitus. This finding in the latter group might be confounded by oral glucose-lowering treatment. GLP-1 does not predict CHD. Although ΔGLP-1 was associated with insulin sensitivity in the type 2 diabetes mellitus group, GLP-1 does not seem to be a predictor of CHD in insulin-resistant patients.
- Nyström T (2008) The potential beneficial role of glucagon-like peptide-1 in endothelial dysfunction and heart failure associated with insulin resistance. Horm Metab Res 40:593–606 CrossRef
- Toft-Nielsen MB, Damholt MB, Madsbad S et al (2001) Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab 86:3717–3723 CrossRef
- Zethelius B, Byberg L, Hales CN, Lithell H, Berne C (2002) Proinsulin is an independent predictor of coronary heart disease: report from a 27-year follow-up study. Circulation 105:2153–2158 CrossRef
- Nyström T, Gutniak MK, Zhang Q et al (2004) Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am J Physiol 287:E1209–E1215 CrossRef
- Byberg L, McKeigue PM, Zethelius B, Lithell HO (2000) Birth weight and the insulin resistance syndrome: association of low birth weight with truncal obesity and raised plasminogen activator inhibitor-1 but not with abdominal obesity or plasma lipid disturbances. Diabetologia 43:54–60 CrossRef
- Merlo J, Lindblad U, Pessah-Rasmussen H et al (2000) Comparison of different procedures to identify probable cases of myocardial infarction and stroke in two Swedish prospective cohort studies using local and national routine registers. Eur J Epidemiol 16:235–243 CrossRef
- DeFronzo RA, Tobin JD, Andres R (1979) Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 237:E214–E223
- Prigeon RL, Quddusi S, Paty B, D'Alessio DA (2003) Suppression of glucose production by GLP-1 independent of islet hormones: a novel extrapancreatic effect. Am J Physiol 285:E701–E707
- Mannucci E, Ognibene A, Cremasco F et al (2001) Effect of metformin on glucagon-like peptide 1 (GLP-1) and leptin levels in obese nondiabetic subjects. Diabetes Care 24:489–494 CrossRef
- Reduced plasma levels of glucagon-like peptide-1 in elderly men are associated with impaired glucose tolerance but not with coronary heart disease
Volume 53, Issue 2 , pp 277-280
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- Coronary heart disease
- Glucagon-like peptide-1
- Impaired glucose tolerance
- Type 2 diabetes
- Industry Sectors
- Author Affiliations
- 1. Department of Internal Medicine, Karolinska Institutet, Södersjukhuset AB, SE-118 83, Stockholm, Sweden
- 2. Department of Public Health and Caring Sciences/Geriatrics, Uppsala University, Uppsala, Sweden
- 3. Department of Medical Sciences, Uppsala University Hospital, Uppsala, Sweden
- 4. Department of Biomedical Sciences, The Panum Institute, University of Copenhagen, Copenhagen, Denmark